AavantiBio, Aldevron partner on gene therapy

By The Science Advisory Board staff writers

July 21, 2021 -- Aldevron made a deal to supply plasmid DNA that will enable AavantiBio to advance its gene therapies for rare genetic diseases.

Aldevron will supply plasmids to AavantiBio's planned vector core and contract development manufacturing organization partners. Also, the partnership includes materials for proof-of-concept and good lab practices (GLP) toxicology studies for future programs.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.